BioNTech Reports €1.1 Billion Loss in 2025 Amid Strategic Pivot and Founder Transition

Key Facts

1BioNTech's full-year 2025 revenues reached €2.9 billion with a net loss of €1.1 billion.

2The company maintains a strong financial position with €17.2 billion in cash, cash equivalents, and security investments.

3Co-founders Ugur Sahin and Özlem Türeci will establish an independent company with a management transition by the end of 2026.

BioNTech SE reported its full-year 2025 financial results, revealing total revenues of €2.9 billion and a net loss of €1.1 billion. Despite the loss, the biotechnology firm maintains a robust financial foundation with €17.2 billion in cash and security investments. The company is currently undergoing a strategic pivot, shifting its focus from COVID-19 vaccines toward a late-stage oncology pipeline. In a significant leadership update, co-founders Ugur Sahin and Özlem Türeci announced they will establish an independent innovation venture, with a full management transition expected by the end of 2026. This transition marks a new era for the company as it seeks to commercialize its mRNA cancer treatments. Investors are weighing the strong liquidity against the uncertainty surrounding the departure of the company's visionary founders.